Synapse - Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)

Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400) Meeting Abstract

Authors:	Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K. L.; Slupe, N.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A.; Noy, A.; Owens, C.; Palomba, M. L.; Kumar, A.; Roeker, L.; Thompson, M. C.; Takvorian, R. W.; Epstein-Peterson, Z. D.; Geyer, M. B.; Salles, G.; Stuver, R.; Caron, P.; Islam, P.; Haque, T.; Ghione, P.; Steiner, R. E.; Torka, P.; David, K. A.; Lue, J. K.; Hamlin, P. A.; Moskowitz, A.; Falchi, L.; Haydu, J.; Johnson, P. C.; Mi, J.; Pendleton, J.; Labarre, A.; Martignetti, R.; Plummer, S. F.; Chabowska, M.; Ramos Amador, W.; Mahajan, N.; Choma, M.; Grieve, C.; Garcia, R. N.; Kelly, H. E.; Mallinger, E.; O'Grady, J.; Beatty, B.; Adams, M.; Apazidis, A.; Cohen, A. C.; Shahkarami, M.; Jacob, A. P.; Abdel-Wahab, O.; Zelenetz, A. D.
Abstract Title:	Multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in treatment-naive chronic lymphocytic leukemia: 5-Year follow up, retreatment outcomes, and Impact of MRD kinetics (ΔMRD400)
Meeting Title:	66th Annual Meeting of the American Society of Hematology (ASH)
Journal Title:	Blood
Volume:	144
Issue:	Suppl. 1
Meeting Dates:	2024 Dec 7-10
Meeting Location:	San Diego, CA
ISSN:	0006-4971
Publisher:	American Society of Hematology
Date Published:	2024-11-05
Start Page:	1867
Language:	English
ACCESSION:	WOS:001412514200036
DOI:	10.1182/blood-2024-205697
PROVIDER:	wos
Notes:	Source: Wos